NBCC supports policies that address systemic deficiencies in the law, regulation, and science policy that result in the approval of drugs that do not significantly extend or save lives and whose prices are not based on value or effectiveness.
News and Resources
Background
The cost of breast cancer care continues to rise. In 2015, the national cost of cancer care totaled $183 billion, and is projected to increase a minimum of 34 percent by 2030—to $246 billion—based solely on the aging and growth of the US population.
This increase does not include anticipated increases in national costs for medical services and prescription drugs, which are predicted to increase during this period by 34 percent and 40 percent, respectively.
Despite the rising cost of prescription drugs, most approved breast cancer drugs have not been shown to extend a patient’s life.
In 2018, federal agencies spent $243 billion on medical and health research and development, much of it on competitive grants for early-stage research. Findings from federally funded research are the basis for the product development work done by private pharmaceutical companies. US tax dollars, allocated through National Institutes of Health (NIH) grants, were used to discover every pharmaceutical product approved by the FDA from 2000 to 2016.
In addition to funding scientific research via grants, the federal government encourages drug development by providing tax incentives. Drugmakers may write off some of the amount they spend each year on research and development using one or a combination of tax incentives.
As patients, we contribute to research by participating in clinical trials, lobbying for research funding, and paying taxes to support it. Our goal is to bring about drugs that will save lives.
Research results are often patented, then sold to industry for millions of dollars. The individual doctor, the institution, and the companies that manufacture the drugs benefit. But in breast cancer, these drugs rarely extend life and cost so much that they often bankrupt patients and the health care system.
Countries like Britain and Germany have taken extensive steps to introduce cost-effectiveness assessments into their health care systems, refusing to pay higher prices for new drugs that do not improve treatment effectiveness over existing options.
US taxpayers pay for public university research, grants, subsidies, and other incentives. This means people are often paying twice for their medicines: through their tax dollars and at the pharmacy. It should be unacceptable for taxpayers to fund the discovery of a new medication that they can’t even afford once it hits the market.
Recent reports show conflicts abound in the current research system. Moreover, due to the focus on financial gain, patients and the public have lost trust in this system.